All articles by Staff Writer
Staff Writer
Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer
SINGAPORE–(BUSINESS WIRE)–Prestige Biopharma has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for PBP1510 (International Non-proprietary name: Ulenistamab), in the treatment of unresectable or metastatic pancreatic adenocarcinoma (PDAC) that has relapsed following and/or is refractory to at least one line of prior therapy.
Kerecis, the Medical-Fish-Skin company, named one of Europe’s fastest growing companies by Financial Times
Kerecis® has been included in the FT1000 list of Europe’s fastest growing companies. The medical-fish-skin company ranked fifth in the healthcare and life sciences category–and 246th overall–in the seventh annual list compiled by the “Financial Times.” This is the first time that Kerecis has been included in the prestigious list.
LEO Pharma presents late-breaking positive Phase 2a efficacy and safety results of LEO 138559 in moderate-to-severe atopic dermatitis at the 2023 AAD Annual Meeting
BALLERUP, Denmark, MARCH 18, 2023 – LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
Active Wound Care Market To Develop Strongly And Cross USD 1,916 million by 2032
New York, March 13, 2023 (GLOBE NEWSWIRE) — According to Market.us, the global active wound care market was valued at around USD 1,137 million in 2022 and is expected to reach approximately USD 1,916 million in 2032, growing at a CAGR of slightly above 5.5% between 2023 and 2032. Active wound care involves a variety of treatments depending on the type and severity of the wound. Active wound care may include cleaning the wound, removing dead tissue, applying dressings, and providing medications. It may also involve controlling any infection, reducing inflammation, promoting healing, and preventing further tissue damage. Other treatments may include the use of pressure garments, hyperbaric oxygen therapy, debridement, skin grafts, or reconstructive surgery.
Altoida announces upcoming poster presentations at AD/PD 2023
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality ,announced two poster presentations at the upcoming AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March 28–April 1, 2023 in Gothenburg, Sweden.
Droplet Biosciences Announces Lymph Diagnostic Platform to Help Prevent Cancer Recurrence
Droplet Biosciences announced an $8 million seed investment to establish proof of concept for the company’s technology. While the lymphatic system’s critical role in metastasis has long been recognized, routine access to patient lymph has been elusive. Droplet’s foundational breakthrough is a non-invasive process to access lymph through the collection of surgical drain fluid after tumor resection. Rich in T-cells, proteins, and other biomarkers, this lymphatic fluid can offer insights into the body’s immune response to cancer earlier and with greater sensitivity than blood.
The Egyptian Authority for Unified Procurement (UPA) and the Arab Hospital Federation (AHF) signed a protocol on cooperation to consolidate the role of the Africa Health ExCon
The Egyptian Authority for Unified Procurement (UPA) and Arab Hospital Federation (AHF) on Tuesday signed a Protocol of Cooperation to enhance the role of the Africa Health ExCon-2023 in its second edition under the title ”Your gateway to Health and Innovation in Africa”.
Aashima Gupta joins Molnlycke’s Board of Directors
Aashima Gupta, Global Director of Healthcare Industry Solutions at Google Cloud, has been elected Board Member at Mölnlycke AB as of 1 March 2023
3M named as one of the world’s Most Ethical Companies by Ethisphere Institute for 10th consecutive year
The Ethisphere Institute today recognized 3M for ethics and integrity in business conduct and compliance for the 10th straight year. 3M is one of only nine industrial companies worldwide to be honored this year.
Finnish diagnostics company Uniogen is developing a test for timely detection of ovarian cancer
Specialised in the diagnostics of infectious and cancer diseases, Uniogen is currently developing, among other things, a test for detecting ovarian cancer. A fast and cost-effective diagnostic test helps detect the difficult-to-diagnose cancer earlier, making it possible to start the right treatment immediately. That, in turn, would improve treatment outcomes.With its proprietary diagnostic tests, Uniogen aims to have a significant impact on the daily lives of both healthcare professionals and patients: tests enabling early detection will improve treatment outcomes and help allocate scarce resources correctly. The company is currently doing its most interesting development work with a test that reveals ovarian cancer. The test detects cancer in a blood sample.